Clinical trials: Nutrition Sciences
Infantile Colic
Evaluation of Safety and Efficacy of New Infant Formula in Infantile Colic
The study is conducted to examine the safety and efficacy of a new infant formula and its effects on the gastrointestinal tolerance in infants suffering from colic.
- Trial name
- Coco (NCT01721850)
- Testing
- control formula, intervention formula 1, intervention formula 2
- Where
- 18 sites in Germany, Italy
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Overweight, Obesity
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people…
- Trial name
- NCT07587710
- Testing
- NNC0487-0111
- Where
- 2 sites in Slovakia
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Nutritional Status, Malnutrition
Nutrition Insights Day Asia
This is an observational, cross-sectional study to be conducted on the Nutrition Insights Day (NID), with retrospective review of patient medical charts. No prospective follow-up period is considered.
- Conditions
- Nutritional Status, Malnutrition, Caloric Deficit, Protein Deficiency
- Trial name
- NCT03606603
- Where
- 89 sites in India, Indonesia and 5 more
- Volunteers
- 590 people
- Sponsor
- Fresenius Kabi
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Enteral Nutrition
Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG)
This is a Multicenter, Open-label, Single-arm study evaluating the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG) in the Nutritional Management of Tube-fed Children Aged 1-4…
- Trial name
- NCT04516213
- Testing
- Enteral Formula With (PHGG)
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes Mellitus, Type 2, Obesity
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Novo Nordisk is developing the study medicine NNC0487-0111 to treat people living with type 2 diabetes and/or people living with overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Overweight
- Trial name
- NCT06559527
- Testing
- NNC0487-0111
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy)…
- Trial name
- NCT00444561
- Testing
- pramlintide acetate
- Where
- 10 sites in United States
- Volunteers
- 184 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents
Children with an excess in body weight, increase the risk of obesity-related co-morbidities and cardiovascular diseases. Childhood obesity may be due to diets laden with fat and lack of physical activity.
- Trial name
- NCT00447291
- Testing
- Supplement: Omega-3 Fish Oil, Multi-Disciplinary Nutrition & Exercise program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Heart Center
Weight Loss, Mood
Effects of Lactobacillus Plantarum KABP-51 Probiotic on Body Composition, Microbiome and Mood in Healthy Overweight Adults
The objective of this study is to recruit 60 healthy moderately overweight subjects to participate in a research study investigating the effects of a specific probiotic strain (Lactobacillus plantarum KABP-51) on measures of…
- Trial name
- NCT06808061
- Testing
- Lactobacillus plantarum
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 3 Waves Wellness
Overweight, Obesity
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with…
- Trial name
- NCT07184632
- Testing
- NNC0662-0419
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
- Trial name
- SCOUT (NCT00234832)
- Testing
- Sibutramine hydrochloride
- Where
- United States
- Volunteers
- 10,777 people
- Sponsor
- Abbott
Overweight or Obesity
The Effect of AMG 133 on Gastric Emptying
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
- Trial name
- NCT07429032
- Testing
- AMG 133, Acetaminophen
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Amgen
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Obesity, Type 2 Diabetes
MagDI Canada Study
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial…
- Trial name
- NCT06467955
- Testing
- Magnet System, DI Biofragmentable
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors.
- Trial name
- NCT06780449
- Testing
- Cagrilintide, Semaglutide
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Malnutrition, Infant, Enteral Feeding Intolerance
Efficacy and Safety of Numeta G13%E Compared to Compounded Parenteral Nutrition in Preterm Neonates
Preterm (PT, born before 37 weeks of gestation) birth complications are the leading causes of death among children aged under 5 years globally, with nearly one million infant deaths reported in 2013.
- Trial name
- NCT06894446
- Testing
- Numeta G13%E, Compounded Parenteral Nutrition (cPN) solution
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baxter Healthcare Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.